The integrin acts upstream of MET in an HGF-independent manner such that treating or plating ovarian, breast, lung or prostate cancer cells with or on integrin substrates, such as fibronectin, collagen or laminin, triggers MET phosphorylation in various cell models [20,26,27,39–41]. This evidence concerns the gene LAMB2 and prostate carcinoma.